Evaluation of menogaril in renal cell carcinoma - A Southwest Oncology Group phase II study (8504)

Ronald L. Stephens, Phyllis Goodman, E. David Crawford, Connie F. Spicer, Bruce A. Lowe, Frederick R. Ahmann, Robert Chapman, Ronald B. Natale

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.

Original languageEnglish (US)
Pages (from-to)S69-S71
JournalInvestigational New Drugs
Volume8
Issue number1 Supplement
DOIs
StatePublished - Mar 1 1990

Keywords

  • menogaril
  • renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Evaluation of menogaril in renal cell carcinoma - A Southwest Oncology Group phase II study (8504)'. Together they form a unique fingerprint.

  • Cite this

    Stephens, R. L., Goodman, P., Crawford, E. D., Spicer, C. F., Lowe, B. A., Ahmann, F. R., Chapman, R., & Natale, R. B. (1990). Evaluation of menogaril in renal cell carcinoma - A Southwest Oncology Group phase II study (8504). Investigational New Drugs, 8(1 Supplement), S69-S71. https://doi.org/10.1007/BF00171987